BLASubcutaneousInjectablePriority Review
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
5/8 — Partial
Priority Review
ALHEMO (concizumab) by Novo Nordisk is tissue factor pathway inhibitor antagonists [moa]. Approved for tissue factor pathway inhibitor antagonist [epc]. First approved in 2024.
Drug data last refreshed 4h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALHEMO (concizumab) is a monoclonal antibody antagonist of Tissue Factor Pathway Inhibitor (TFPI) approved in December 2024 for hemophilia treatment. It works by blocking TFPI to enhance the intrinsic coagulation pathway, restoring hemostatic balance in patients with bleeding disorders. This novel mechanism offers an alternative to traditional factor replacement therapy.
Growth
Early-stage growth product with fresh market entry creates expansion opportunities for commercial and medical affairs teams.
Mechanism of Action
Tissue Factor Pathway Inhibitor Antagonists
Pharmacologic Class:
Tissue Factor Pathway Inhibitor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (9)
Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo
Started May 2025
30 enrolled
Haemophilia A, Haemophilia B
Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors
Started Aug 2024
23 enrolled
Haemophilia AHaemophilia B
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
Started Mar 2022
153 enrolled
Haemophilia A and B With and Without Inhibitors
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
Started Nov 2019
156 enrolled
Haemophilia A Without InhibitorsHaemophilia B Without Inhibitors
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors
Started Oct 2019
134 enrolled
Haemophilia A With InhibitorsHaemophilia B With Inhibitors
Worked on ALHEMO at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.